Articles by Meso Foundation

Can pemetrexed’s (Alimta) effectiveness in mesothelioma treatment be improved?

In 2004, over 14 years ago (!), the FDA approved the first ever (and the last so far) mesothelioma treatment drug – Alimta (pemetrexed) in combination with cisplatin. The treatment is now very much considered standard and for some patients the results are dramatic. Unfortunately, patients and physicians alike are well aware of its limitations. […]


Meet and greet our new communications associate

We are happy to welcome Trey Meehan – our new communications associate – to the Meso Foundation! He joined us earlier this month and will be assisting with the management and development of our online and offline communications.
Trey brings a knowledge of nonprofit and public health communications as well as a desire to serve mission-driven organizations […]


Congress funds congressionally directed DOD funding for FY18 with $80 million

We are excited to report that Congress has funded the congressionally directed Department of Defense (DoD) funding for Fiscal Year 2018 (FY18) with $80 million to support innovative, high-impact cancer research. This is a major increase from last year’s $60 million, $50 million the year before, and $25 million two years prior. The upward trend, in […]



The Meso Foundation supports the ‘Alan Reinstein Ban Asbestos Act of 2017’

The Mesothelioma Applied Research Foundation (Meso Foundation) commends the efforts of Sen. Jeff Merkley (D-OR) and the Asbestos Disease Awareness Organization (ADAO) for the introduction of S. 2072, the “Alan Reinstein Ban Asbestos Act of 2017,” legislation to amend the Toxic Substances Control Act to require the Environmental Protection Agency to identify and assess known uses […]